Molecular characterization of ovarian cancer by gene-expression profiling

Gynecologic Oncology

Volumn 118, Issue 1, 2010, Pages 88-92

  Gomez Raposo C ^a   Mendiola, M ^b   Barriuso, J ^b   Hardisson, D ^b   Redondo, A ^b  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Gene expression profiling; Histological subtypes; Microarray; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CLEAR CELL CARCINOMA; CLINICAL TRIAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; MICROARRAY ANALYSIS; MUCINOUS CARCINOMA; OVARY CANCER; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

FEMALE; GENE EXPRESSION PROFILING; HUMANS; OVARIAN NEOPLASMS;

EID: 77953288814     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.03.012     Document Type: Review

References (37)

1. Cannistra S.A. Cancer of the ovary. New Engl J Med 351 (2004) 2519-2529
2. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
3. Feeley K.M., and Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 38 (2001) 87-95
4. Berek J.S., Thomas G.M., and Ozols R.F. Ovarian Cancer. In: Bast R.J.C., Kufe D.W., Pollack J.R., Weichselbaum R.R., Holland J.F., and Frei E.I. (Eds). Cancer medicine. 5th ed. (2000), B.C. Decker, Inc., London 1687-1720
5. Aunoble B., Sanches R., Didier E., and Bignon Y.J. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. Int J Oncol 16 (2000) 567-576
6. Jazaeri A.A., Lu K., Schmandt R., Harris C.P., Rao P.H., Sotiriou C., et al. Molecular determinats of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 36 (2003) 53-59
7. Lu K.H., Patterson A.P., Wang L., Marquez R.T., Atkinson E.N., Baggerly K.A., et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10 (2004) 3291-3300
8. Schwartz D., Kardia S., Shedden K., Kuick R., Michailidis G., Taylor J.M., et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62 (2002) 4722-4729
9. Zorn K.K., Bonome T., Gangi L., Chandramouli G.V., Awtrey C.S., Gardner G.J., et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11 (2005) 6422-6430
10. Pavelka J.C., Li A.J., and Karlan B.Y. Hereditary ovarian cancerdassessing risk and prevention strategies. Obstet Gynecol Clin North Am 34 (2007) 651-665
11. Jazaeri A.A., Yee C.J., Sotiriou C., Brantley K.R., Boyd J., and Liu E.T. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 94 (2002) 990-1000
12. Jazaeri A.A. Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease. Mol Oncol 3 (2009) 151-156
13. Shih I.-M., and Kurman R.J. Ovarian tumorigenesis: a proposed model based on orphological and molecular genetic analysis. Am J Pathol 164 (2004) 1511-1518
14. Zanetta G., Rota S., Chiari S., Bonazzi C., Bratina G., and Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 19 10 (2001) 2658-2664
15. Silva E.G., Tornos C., Zhuang Z., Merino M.J., and Gershenson D.M. Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential. Int J Gynecol Pathol 17 1 (1998) 1-6
16. Longacre T.A., McKenney J.K., Tazelaar H.D., Kempson R.L., and Hendrickson M.R. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or = 5-year) follow-up. Am J Surg Pathol. 29 6 (2005 Jun) 707-723
17. Bell D.A., and Scully R.E. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 73 (1994) 1859-1864
18. Gilks C.B., Vandehyden B.C., Zhu S., van de Rijn M., and Longacre T.A. Distinction between serous tumors of low malignant potential and serous cancinomas based on global mRNA expression profiling. Gynecol Oncol 96 (2005) 684-694
19. Bonome T., et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65 (2005) 10602-10612
20. Meinhold-Heerlein I., Bauerschlag D., Hilpert F., Dimitrov P., Sapinoso L.M., Orlowska-Volk M., et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24 (2005) 1053-1065
21. Marchini S., Mariani P., Chiorino G., Marrazzo E., Bonomi R., Fruscio R., et al. Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res 14 23 (2008) 7850-7860
22. Chien J., Fan J.B., Bell D.A., April C., Klotzle B., Ota T., et al. Analysis of gene espression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol 114 (2009) 3-11
23. Singer G., Kurman R.J., Chang H.W., Cho S.K., and Shih I.eM. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160 (2002) 1223-1228
24. Teneriello M.G., Ebina M., Linnoila R.I., Henry M., Nash J.D., Park R.C., et al. p53 and K-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 53 (1993) 3103-3108
25. Chan W.Y., Cheung K.K., Schorge J.O., Huang L.W., Welch W.R., Bell D.A., et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 156 (2000) 409-417
26. Riopel M.A., Ronnett B.M., and Kurman R.J. Evaluation of diagnostic criteria and behavior of ovarian intestinaltype mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 23 (1999) 617-635
27. Shridhar V., Lee J., Pandita A., Iturra S., Avula R., Staub J., et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 61 (2008) 5895-5904
28. Berchuck A., Iversen E.S., Lancaster J.M., Pittman J., Luo J., Lee P., et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11 (2005) 3686-3696
29. Berchuck A., Iversen E.S., Luo J., Clarke J.P., Horne H., Levien D.A., et al. Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favourable Outcome. Clin Cancer Res 15 7 (2009) 2448-2455
30. Wamunyokoli F.W., Bonme T., Lee J.Y., Feltmate C.M., Welch W.R., Radonovich M., et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res 12 3 (2006) 690-700
31. Tothill R.X., Tinker A.V., George J., Brown R., Fox S.B., Lade S., et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome. Clin Cancer Res 14 16 (2008) 5198-5208
32. Dressman H.K., Berchuck A., Chan G., Zhai J., Bild A., Sayer R., et al. An integrated genomic based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25 (2007) 517-525
33. Berchuck A. Microarray analysis of gene expression in gynecologic cancers - still only the beginning. Gynecol Oncol 114 (2009) 1-2
34. Dupuy A., and Simon R.M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99 (2007) 147-157
35. Konstantinopoulos P.A., Spentzos D., and Cannistra S.A. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract 5 10 (2008) 577-587
36. Simon R., Radmacher M.D., Dobbin K., and McShane L.M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95 (2003) 14-18
37. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826